Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Dennis Selkoe
Brigham and Women's Hospital, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Prothena Corporation plc
Equity Interest - Publicly traded entity (e.g., stock, stock option, or other ownership interest)
The grant proposes to characterize how unfolded monomeric α-synuclein triggers its C-Terminal-truncation and subsequent abnormal aggregation by characterizing mutant forms of the protein that cannot fold into physiological α-helical tetramers/multimers. Prothena is currently testing an investigational anti- α-synuclein monoclonal antibody (PRX002), which is designed to reduce the levels of C-Terminal-truncated α-synuclein and subsequent neurotoxicity for the treatment of Parkinson’s disease. The Institution determined that Dr. Selkoe’s financial interest was related to the research, and that the financial interest could directly and significantly affect the design, conduct, or reporting of the research. Therefore, the financial interest creates a conflict of interest with this grant under PHS regulations. Nonetheless, the Institution determined that this conflict of interest can be managed with the implementation of management measures.
Shifting Multimers: New mouse and culture models of α-synuclein truncation by calpain in PD
Our research grant addresses a critical public health concern by filling gaps in our understanding of the mechanisms of ?Syn truncation and aggregation and their relationship to neuronal death in PD and related human diseases. The overall goal is (1) to exploit our recent finding that an excess of aSyn monomers arising from abrogation of physiological ?Syn multimers provides substrates for adverse proteolytic cleavage; and (2) to use tetramer-abolishing mutants as well as models of toxin-induced protease activity to guide the future generation of protease inhibitors for treating PD and DLB.��
Filed on August 29, 2017.
Tell us what you know about Dennis Selkoe's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Dennis Selkoe filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Dennis Selkoe | Brigham and Women's Hospital | Conflict of Interest | Prothena Corporation plc | $40,000 - $59,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.